摘要:
The invention relates to antibody fragments with simple heavy chain or sdAbs, characterized in that they consist of anti HIV Nef-protein fragments corresponding to all or a portion of the HHV domains of camelids, particularly llamas.
摘要:
The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.
摘要:
The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
摘要:
The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell.
摘要:
The present invention relates to a method for preparing sd Ab microarray comprising the step consisting of: —i) providing a host cell capable of expressing a biotinylation enzyme —ii) transforming said host cell with a nucleic acid encoding for a fusion protein wherein a single domain antibody is fused at its carboxy terminal end to a biotinylation peptide —iii) culturing said host cell in presence of biotin in such a way that said fusion protein and biotinylation enzyme are expressed, resulting in biotinylation of said fusion protein —iv) lysing said host cell as cultured at step iii) —v) spotting the lysate obtained at step iv) on a solid sup port coated with an agent selected from the group consisting of avidin, streptavidin and/or any art known derivative of these agents A further object of the invention relates to a sd Ab microarray obtainable by the method of the invention.
摘要:
The invention relates to novel purified insulated peptides, which exhibit, in particular, Nef protein-binding properties and are characterised in that they contain an amino acid sequence of a formula SEQ ID No 1: W-P-a-W-L-P, wherein a is selected from W, A, S or D.
摘要翻译:本发明涉及新颖的纯化的绝缘肽,其特别表现出Nef蛋白结合性质,其特征在于它们含有式SEQ ID NO:WPaWLP的氨基酸序列,其中a选自W,A, S或D.
摘要:
The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of:—a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and,—a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
摘要:
The invention relates to antibody fragments with simple heavy chain or sdAbs, characterised in that they consist of anti HIV Nef-protein fragments corresponding to all or a portion of the HHV domains of camelids, particularly llamas.
摘要:
The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.
摘要:
The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.